These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 34418455)
21. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
22. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009 [TBL] [Abstract][Full Text] [Related]
24. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480 [TBL] [Abstract][Full Text] [Related]
25. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Kuai R; Yuan W; Li W; Qin Y; Tang J; Yuan M; Fu L; Ran R; Zhang Z; He Q Mol Pharm; 2011 Dec; 8(6):2151-61. PubMed ID: 21981683 [TBL] [Abstract][Full Text] [Related]
26. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670 [TBL] [Abstract][Full Text] [Related]
28. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726 [TBL] [Abstract][Full Text] [Related]
29. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902 [TBL] [Abstract][Full Text] [Related]
30. Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency. Li Y; Yang D; Wang Y; Li Z; Zhu C Int J Nanomedicine; 2019; 14():301-315. PubMed ID: 30643408 [TBL] [Abstract][Full Text] [Related]
31. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel. Gu Z; Chang M; Fan Y; Shi Y; Lin G Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079 [TBL] [Abstract][Full Text] [Related]
32. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852 [TBL] [Abstract][Full Text] [Related]
33. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib. Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998 [TBL] [Abstract][Full Text] [Related]
35. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
36. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy. Zhang J; Zheng Y; Xie X; Wang L; Su Z; Wang Y; Leong KW; Chen M Mol Pharm; 2017 Nov; 14(11):3644-3659. PubMed ID: 28994600 [TBL] [Abstract][Full Text] [Related]
37. pH-Sensitive, Long-Circulating Liposomes as an Alternative Tool to Deliver Doxorubicin into Tumors: a Feasibility Animal Study. Silva JO; Fernandes RS; Lopes SC; Cardoso VN; Leite EA; Cassali GD; Marzola MC; Rubello D; Oliveira MC; de Barros AL Mol Imaging Biol; 2016 Dec; 18(6):898-904. PubMed ID: 27172938 [TBL] [Abstract][Full Text] [Related]
38. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study. Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656 [TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma. Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570 [TBL] [Abstract][Full Text] [Related]
40. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor. Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]